Replimune Group

Replimune is a pioneer in the next generation of cancer treatments, known as oncolytic immunotherapy. These ingeniously designed therapies combine multiple mechanisms of action, enhancing the ability of viruses to replicate and kill cancer cells, while generating a powerful systemic anti-tumor immune response tailored to each patient.Oncolytic immunotherapy holds the promise of improving the effectiveness of immune checkpoint blockade and becoming the second cornerstone of cancer immunotherapy, moving beyond incremental advancements in cancer treatment to help more patients overcome the disease.